Primary graft dysfunction

Proceedings of the American Thoracic Society

Volumn 6, Issue 1, 2009, Pages 39-46

  Lee, James C ^a   Christie, Jason D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Lung transplantation; Primary graft dysfunction

Indexed keywords

ACETYLCYSTEINE; COLLAGEN TYPE 5; COMPLEMENT COMPONENT C1S INHIBITOR; GINKGOLIDE B; GLYCERYL TRINITRATE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NITRIC OXIDE; PLACEBO; PRESERVATIVE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; VASCULOTROPIN;

ARTIFICIAL VENTILATION; ASPIRATION PNEUMONIA; BLOOD TRANSFUSION; BRONCHIOLITIS OBLITERANS; CARDIOPULMONARY BYPASS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EXTRACORPOREAL OXYGENATION; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART BEAT; HEART TRANSPLANTATION; HUMAN; INCIDENCE; LUNG FUNCTION; LUNG TRANSPLANTATION; MOLECULAR GENETICS; NONHUMAN; ORGAN DONOR; ORGAN PRESERVATION; OUTCOME ASSESSMENT; PATHOGENESIS; PROTEIN BLOOD LEVEL; REPERFUSION INJURY; REVIEW; RISK FACTOR;

BIOLOGICAL MARKERS; BRONCHIOLITIS OBLITERANS; GRAFT REJECTION; HUMANS; INCIDENCE; LUNG; LUNG DISEASES; LUNG TRANSPLANTATION; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 58549096506     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200808-082GO     Document Type: Review

References (97)

1. Christie JD, Bavaria JE, Palevsky HI, Litzky L, Blumenthal NP, Kaiser LR, Kotloff RM. Primary graft failure following lung transplantation. Chest 1998;114:51-60.
2. King RC, Binns OA, Rodriguez F, Kanithanon RC, Daniel TM, Spotnitz WD, Tribble CG, Kron IL. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000;69:1681-1685.
3. Christie JD, Kotloff RM, Pochettino A, Arcasoy SM, Rosengard BR, Landis JR, Kimmel SE. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003;124:1232-1241.
4. Arcasoy SM, Kotloff RM. Lung transplantation. N Engl J Med 1999;340:1081-1091.
5. Christie JD, Sager JS, Kimmel SE, Ahya VN, Gaughan C, Blumenthal NP, Kotloff RM. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005;127:161-165.
6. Arcasoy SM, Fisher A, Hachem RR, Scavuzzo M, Ware LB. Report of the ISHLT working group on primary lung graft dysfunction: Part V. Predictors and outcomes. J Heart Lung Transplant 2005;24:1483-1488.
7. Christie JD, Kotloff RM, Ahya VN, Tino G, Pochettino A, Gaughan C, DeMissie E, Kimmel SE. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005;171:1312-1316.
8. Christie JD, Van Raemdonck D, de Perrot M, Barr M, Keshavjee S, Arcasoy S, Orens J. Report of the ISHLT working group on primary lung graft dysfunction: Part I. Introduction and methods. J Heart Lung Transplant 2005;24:1451-1453.
9. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT working group on primary lung graft dysfunction: Part II. Definition. J Heart Lung Transplant 2005;24:1454-1459.
10. Daud SA, Yusen RD, Meyers BF, Chakinala MM, Walter MJ, Aloush AA, Patterson GA, Trulock EP, Hachem RR. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007;175:507-513.
11. Barr ML, Kawut SM, Whelan TP, Girgis R, Bottcher H, Sonett J, Vigneswaran W, Follette DM, Corris PA. Report of the ISHLT working group on primary lung graft dysfunction: Part IV. Recipient-related risk factors and markers. J Heart Lung Transplant 2005;24:1468-1482.
12. Whitson BA, Nath DS, Johnson AC, Walker AR, Prekker ME, Radosevich DM, Herrington CS, Dahlberg PS. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2006;131:73-80.
13. Prekker ME, Herrington CS, Hertz MI, Radosevich DM, Dahlberg PS. Early trends in Pao(2)/fraction of inspired oxygen ratio predict outcome in lung transplant recipients with severe primary graft dysfunction. Chest 2007;132:991-997.
14. Oto T, Levvey BJ, Snell GI. Potential refinements of the international society for heart and lung transplantation primary graft dysfunction grading system. J Heart Lung Transplant 2007;26:431-436.
15. Oto T, Griffiths AP, Levvey BJ, Pilcher DV, Williams TJ, Snell GI. Definitions of primary graft dysfunction after lung transplantation: differences between bilateral and single lung transplantation. J Thorac Cardiovasc Surg 2006;132:140-147.
16. Fiser SM, Kron IL, McLendon Long S, Kaza AK, Kern JA, Tribble CG. Early intervention after severe oxygenation index elevation improves survival following lung transplantation. J Heart Lung Transplant 2001;20:631-636.
17. Khan SU, Salloum J, O'Donovan PB, Mascha EJ, Mehta AC, Matthay MA, Arroliga AC. Acute pulmonary edema after lung transplantation: the pulmonary reimplantation response. Chest 1999;116:187-194.
18. Thabut G, Vinatier I, Stern JB, Leseche G, Loirat P, Fournier M, Mal H. Primary graft failure following lung transplantation: predictive factors of mortality. Chest 2002;121:1876-1882.
19. Burton CM, Iversen M, Milman N, Zemtsovski M, Carlsen J, Steinbruchel D, Mortensen J, Andersen CB. Outcome of lung transplanted patients with primary graft dysfunction. Eur J Cardiothorac Surg 2007;31:75-82.
20. Prekker ME, Nath DS, Walker AR, Johnson AC, Hertz MI, Herrington CS, Radosevich DM, Dahlberg PS. Validation of the proposed international society for heart and lung transplantation grading system for primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2006;25:371-378.
21. Whitson BA, Prekker ME, Herrington CS, Whelan TP, Radosevich DM, Hertz MI, Dahlberg PS. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant 2007;26:1004-1011.
22. Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, Jones DR, Robbins MK, Kron IL. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002;73:1041-1047.
23. Fisher AJ, Wardle J, Dark JH, Corris PA. Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant 2002;21:1206-1212.
24. Girgis RE, Tu I, Berry GJ, Reichenspurner H, Valentine VG, Conte JV, Ting A, Johnstone I, Miller J, Robbins RC, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996;15:1200-1208.
25. Hachem RR, Khalifah AP, Chakinala MM, Yusen RD, Aloush AA, Mohanakumar T, Patterson GA, Trulock EP, Walter MJ. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation 2005;80:1406-1413.
26. Khalifah AP, Hachem RR, Chakinala MM, Yusen RD, Aloush A, Patterson GA, Mohanakumar T, Trulock EP, Walter MJ. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant 2005;5:2022-2030.
27. Meyer DM, Bennett LE, Novick RJ, Hosenpud JD. Effect of donor age and ischemic time on intermediate survival and morbidity after lung transplantation. Chest 2000;118:1255-1262.
28. de Perrot M, Bonser RS, Dark J, Kelly RF, McGiffin D, Menza R, Pajaro O, Schueler S, Verleden GM. Report of the ISHLT working group on primary lung graft dysfunction: Part III. Donor-related risk factors and markers. J Heart Lung Transplant 2005;24:1460-1467.
29. Oto T, Griffiths AP, Levvey B, Pilcher DV, Whitford H, Kotsimbos TC, Rabinov M, Esmore DS, Williams TJ, Snell GI. A donor history of smoking affects early but not late outcome in lung transplantation. Transplantation 2004;78:599-606.
30. Lee JC, Kuntz CL, Hadjiliadis D, Ahya VN, Kawut SM, Wille K, Lama VN, Millstone A, Orens J, Weinacker A, et al. Risk factors for early vs. late primary graft dysfunction [abstract]. Am J Respir Crit Care Med 2008;177:A396.
31. Cassivi SD, Meyers BF, Battafarano RJ, Guthrie TJ, Trulock EP, Lynch JP, Cooper JD, Patterson GA. Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg 2002;74:1663-1669. (discussion 1669-1670).
32. Sommers KE, Griffith BP, Hardesty RL, Keenan RJ. Early lung allograft function in twin recipients from the same donor: risk factor analysis. Ann Thorac Surg 1996;62:784-790.
33. Szeto WY, Kreisel D, Karakousis GC, Pochettino A, Sterman DH, Kotloff RM, Arcasoy SM, Zisman DA, Blumenthal NP, Gallop RJ, et al. Cardiopulmonary bypass for bilateral sequential lung transplantation in patients with chronic obstructive pulmonary disease without adverse effect on lung function or clinical outcome. J Thorac Cardiovasc Surg 2002;124:241-249.
34. Wang Y, Kurichi JE, Blumenthal NP, Ahya VN, Christie JD, Pochettino A, Kaiser LR, Sonnad SS, Pollak ES. Multiple variables affecting blood usage in lung transplantation. J Heart Lung Transplant 2006;25:533-538.
35. Webert KE, Blajchman MA. Transfusion-related acute lung injury. Transfus Med Rev 2003;17:252-262.
36. Covarrubias M, Ware LB, Kawut SM, De Andrade J, Milstone A, Weinacker A, Orens J, Lama V, Wille K, Bellamy S, et al. Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007;7:2573-2578.
37. Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 2001;41:264-268.
38. de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003;167:490-511.
39. Miotla JM, Jeffery PK, Hellewell PG. Platelet-activating factor plays a pivotal role in the induction of experimental lung injury. Am J Respir Cell Mol Biol 1998;18:197-204.
40. Serrick C, Adoumie R, Giaid A, Shennib H. The early release of interleukin-2, tumor necrosis factor-alpha and interferon-gamma after ischemia reperfusion injury in the lung allograft. Transplantation 1994;58:1158-1162.
41. Moreno I, Vicente R, Ramos F, Vicente JL, Barbera M. Determination of interleukin-6 in lung transplantation: association with primary graft dysfunction. Transplant Proc 2007;39:2425-2426.
42. van der Kaaij NP, Kluin J, Haitsma JJ, den Bakker MA, Lambrecht BN, Lachmann B, de Bruin RW, Bogers AJ. Ischemia of the lung causes extensive long-term pulmonary injury: an experimental study. Respir Res 2008;9:28.
43. Yoshida S, Haque A, Mizobuchi T, Iwata T, Chiyo M, Webb TJ, Baldridge LA, Heidler KM, Cummings OW, Fujisawa T, et al. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant 2006;6:724-735.
44. Bobadilla JL, Love RB, Jankowska-Gan E, Xu Q, Haynes LD, Braun RK, Hayney MS, Munoz del Rio A, Meyer K, Greenspan DS, et al. Th-17, monokines, collagen type v, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med 2008;177:660-668.
45. Iwata T, Chiyo M, Yoshida S, Smith GN Jr, Mickler EA, Presson R Jr, Fisher AJ, Brand DD, Cummings OW, Wilkes DS. Lung transplant ischemia reperfusion injury: metalloprotease inhibition down-regulates exposure of type v collagen, growth-related oncogene-induced neutrophil chemotaxis, and tumor necrosis factor-alpha expression. Transplantation 2008;85:417-426.
46. Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, Meyer KC, Hayney MS, Braun RK, Greenspan DS, et al. IL-17-dependent cellular immunity to collagen type v predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007;117:3498-3506.
47. Bharat A, Kuo E, Steward N, Aloush A, Hachem R, Trulock EP, Patterson GA, Meyers BF, Mohanakumar T. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg 2008;86:189-195.
48. Frank MM. Complement in the pathophysiology of human disease. N Engl J Med 1987;316:1525-1530.
49. Westall GP, Snell GI, McLean C, Kotsimbos T, Williams T, Magro C. C3d and c4d deposition early after lung transplantation. J Heart Lung Transplant 2008;27:722-728.
50. Shargall Y, Guenther G, Ahya VN, Ardehali A, Singhal A, Keshavjee S. Report of the ISHLT working group on primary lung graft dysfunction: Part VI. Treatment. J Heart Lung Transplant 2005;24:1489-1500.
51. Meade MO, Granton JT, Matte-Martyn A, McRae K, Weaver B, Cripps P, Keshavjee SH. A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation. Am J Respir Crit Care Med 2003;167:1483-1489.
52. Botha P, Jeyakanthan M, Rao JN, Fisher AJ, Prabhu M, Dark JH, Clark SC. Inhaled nitric oxide for modulation of ischemia-reperfusion injury in lung transplantation. J Heart Lung Transplant 2007;26:1199-1205.
53. Keshavjee S, Davis RD, Zamora MR, de Perrot M, Patterson GA. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg 2005;129:423-428.
54. Zamora MR, Davis RD, Keshavjee SH, Schulman L, Levin J, Ryan U, Patterson GA. Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial. Chest 1999;116:46S.
55. Wittwer T, Grote M, Oppelt P, Franke U, Schaefers HJ, Wahlers T. Impact of PAF antagonist BN 52021 (ginkolide b) on post-ischemic graft function in clinical lung transplantation. J Heart Lung Transplant 2001;20:358-363.
56. Thabut G, Vinatier I, Brugiere O, Leseche G, Loirat P, Bisson A, Marty J, Fournier M, Mal H. Influence of preservation solution on early graft failure in clinical lung transplantation. Am J Respir Crit Care Med 2001;164:1204-1208.
57. Oto T, Griffiths AP, Rosenfeldt F, Levvey BJ, Williams TJ, Snell GI. Early outcomes comparing Perfadex, Euro-Collins, and Papworth solutions in lung transplantation. Ann Thorac Surg 2006;82:1842-1848.
58. Schnickel GT, Ross DJ, Beygui R, Shefizadeh A, Laks H, Saggar R, Lynch JP III, Ardehali A. Modified reperfusion in clinical lung transplantation: the results of 100 consecutive cases. J Thorac Cardiovasc Surg 2006;131:218-223.
59. Lee JC, Bhora F, Sun J, Cheng G, Arguiri E, Solomides CC, Chatterjee S, Christofidou-Solomidou M. Dietary flaxseed enhances antioxidant defenses and is protective in amousemodel of lung ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol 2008;294:L255-L265.
60. Sun J, Guo W, Ben Y, Jiang J, Tan C, Xu Z, Wang X, Bai C. Preventive effects of curcumin and dexamethasone on lung transplantation-associated lung injury in rats. Crit Care Med 2008;36:1205-1213.
61. Adatia I, Lillehei C, Arnold JH, Thompson JE, Palazzo R, Fackler JC, Wessel DL. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994;57:1311-1318.
62. Date H, Triantafillou AN, Trulock EP, Pohl MS, Cooper JD, Patterson GA. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 1996;111:913-919.
63. Macdonald P, Mundy J, Rogers P, Harrison G, Branch J, Glanville A, Keogh A, Spratt P. Successful treatment of life-threatening acute reperfusion injury after lung transplantation with inhaled nitric oxide. J Thorac Cardiovasc Surg 1995;110:861-863.
64. Garat C, Jayr C, Eddahibi S, Laffon M, Meignan M, Adnot S. Effects of inhaled nitric oxide or inhibition of endogenous nitric oxide formation on hyperoxic lung injury. Am J Respir Crit Care Med 1997;155:1957-1964.
65. Meyers BF, Sundt TM III, Henry S, Trulock EP, Guthrie T, Cooper JD, Patterson GA. Selective use of extracorporeal membrane oxygenation is warranted after lung transplantation. J Thorac Cardiovasc Surg 2000;120:20-26.
66. Smedira NG, Moazami N, Golding CM, McCarthy PM, Apperson-Hansen C, Blackstone EH, Cosgrove DM III. Clinical experience with 202 adults receiving extracorporeal membrane oxygenation for cardiac failure: survival at five years. J Thorac Cardiovasc Surg 2001;122:92-102.
67. Fischer S, Bohn D, Rycus P, Pierre AF, de Perrot M, Waddell TK, Keshavjee S. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: analysis of the extracorporeal life support organization (ELSO) registry. J Heart Lung Transplant 2007;26:472-477.
68. Wigfield CH, Lindsey JD, Steffens TG, Edwards NM, Love RB. Early institution of extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation improves outcome. J Heart Lung Transplant 2007;26:331-338.
69. Glassman LR, Keenan RJ, Fabrizio MC, Sonett JR, Bierman MI, Pham SM, Griffith BP. Extracorporeal membrane oxygenation as an adjunct treatment for primary graft failure in adult lung transplant recipients. J Thorac Cardiovasc Surg 1995;110:723-726. (discussion 726-727).
70. Aigner C, Wisser W, Taghavi S, Lang G, Jaksch P, Czyzewski D, Klepetko W. Institutional experience with extracorporeal membrane oxygenation in lung transplantation. Eur J Cardiothorac Surg 2007;31:468-473. (discussion 473-464).
71. Ko WJ, Chen YS, Lee YC. Replacing cardiopulmonary bypass with extracorporeal membrane oxygenation in lung transplantation operations. Artif Organs 2001;25:607-612.
72. Bittner HB, Binner C, Lehmann S, Kuntze T, Rastan A, Mohr FW. Replacing cardiopulmonary bypass with extracorporeal membrane oxygenation in lung transplantation operations. Eur J Cardiothorac Surg 2007;31:462-467. (discussion 467).
73. Ko WJ, Chen YS, Luh SP, Lee YC, Chu SH. Extracorporeal membrane oxygenation support for single-lung transplantation in patients with primary pulmonary hypertension. Transplant Proc 1999;31:166-168.
74. Pereszlenyi A, Lang G, Steltzer H, Hetz H, Kocher A, Neuhauser P, Wisser W, Klepetko W. Bilateral lung transplantation with intra- and postoperatively prolonged ECMO support in patients with pulmonary hypertension. Eur J Cardiothorac Surg 2002;21:858-863.
75. Hohlfeld JM, Struber M, Ahlf K, Hoeper MM, Fraund S, Krug N, Warnecke G, Harringer W, Haverich A, Fabel H. Exogenous surfactant improves survival and surfactant function in ischaemia-reperfusion injury in minipigs. Eur Respir J 1999;13:1037-1043.
76. Novick RJ, Gilpin AA, Gehman KE, Ali IS, Veldhuizen RA, Duplan J, Denning L, Possmayer F, Bjarneson D, Lewis JF. Mitigation of injury in canine lung grafts by exogenous surfactant therapy. J Thorac Cardiovasc Surg 1997;113:342-353.
77. Erasmus ME, Hofstede GJ, Petersen AH, Haagsman HP, Oetomo SB, Prop J. Effects of early surfactant treatment persisting for one week after lung transplantation in rats. Am J Respir Crit Care Med 1997;156:567-572.
78. Friedrich I, Borgermann J, Splittgerber FH, Brinkmann M, Reidemeister JC, Silber RE, Seeger W, Schmidt R, Gunther A. Bronchoscopic surfactant administration preserves gas exchange and pulmonary compliance after single lung transplantation in dogs. J Thorac Cardiovasc Surg 2004;127:335-343.
79. Gunther A, Balser M, Schmidt R, Markart P, Olk A, Borgermann J, Splittgerber FH, Seeger W, Friedrich I. Surfactant abnormalities after single lung transplantation in dogs: impact of bronchoscopic surfactant administration. J Thorac Cardiovasc Surg 2004;127:344-354.
80. Kermeen FD, McNeil KD, Fraser JF, McCarthy J, Ziegenfuss MD, Mullany D, Dunning J, Hopkins PM. Resolution of severe ischemia-reperfusion injury post-lung transplantation after administration of endobronchial surfactant. J Heart Lung Transplant 2007;26:850-856.
81. Inci I, Zhai W, Arni S, Hillinger S, Vogt P, Weder W. N-acetylcysteine attenuates lung ischemia-reperfusion injury after lung transplantation. Ann Thorac Surg 2007;84:240-246. (discussion 246).
82. Chamogeorgakis TP, Kostopanagiotou GG, Kalimeris CA, Kabouroglou GI, Kourtesis AN, Routsi CI, Dima CC, Toumpoulis IK. Effect of n-acetyl-l-cysteine on lung ischaemia reperfusion injury in a porcine experimental model. ANZ J Surg 2008;78:72-77.
83. Wolf PS, Merry HE, Farivar AS, McCourtie AS, Mulligan MS. Stress-activated protein kinase inhibition to ameliorate lung ischemia reperfusion injury. J Thorac Cardiovasc Surg 2008;135:656-665.
84. dos Santos CC, Okutani D, Hu P, Han B, Crimi E, He X, Keshavjee S, Greenwood C, Slutsky AS, Zhang H, et al. Differential gene profiling in acute lung injury identifies injury-specific gene expression. Crit Care Med 2008;36:855-865.
85. Li J, Nie J, Chen G, Gong Y, Jiang K, Yang G, Liu L, Wang J. Gene expression profile of pulmonary tissues in different phases of lung ischemia-reperfusion injury in rats. J Huazhong Univ Sci Technolog Med Sci 2007;27:564-570.
86. Ray M, Dharmarajan S, Freudenberg J, Zhang W, Patterson GA. Expression profiling of human donor lungs to understand primary graft dysfunction after lung transplantation. Am J Transplant 2007;7:2396-2405.
87. Calfee CS, Budev MM, Matthay MA, Church G, Brady S, Uchida T, Ishizaka A, Lara A, Ranes JL, deCamp MM, et al. Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. J Heart Lung Transplant 2007;26:675-680.
88. Krenn K, Klepetko W, Taghavi S, Lang G, Schneider B, Aharinejad S. Recipient vascular endothelial growth factor serum levels predict primary lung graft dysfunction. Am J Transplant 2007;7:700-706.
89. Fisher AJ, Donnelly SC, Hirani N, Haslett C, Strieter RM, Dark JH, Corris PA. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am J Respir Crit Care Med 2001;163:259-265.
90. Kaneda H, Waddell TK, de Perrot M, Bai XH, Gutierrez C, Arenovich T, Chaparro C, Liu M, Keshavjee S. Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans. Am J Transplant 2006;6:544-551.
91. Christie JD, Robinson N, Ware LB, Plotnick M, De Andrade J, Lama V, Milstone A, Orens J, Weinacker A, Demissie E, et al. Association of protein c and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 2007;175:69-74.
92. Botha P, Trivedi D, Searl CP, Corris PA, Schueler SV, Dark JH. Differential pulmonary vein gases predict primary graft dysfunction. Ann Thorac Surg 2006;82:1998-2002.
93. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999;130:515-524.
94. Neyrinck AP, Van De Wauwer C, Geudens N, Rega FR, Verleden GM, Wouters P, Lerut TE, Van Raemdonck DE. Comparative study of donor lung injury in heart-beating versus non-heart-beating donors. Eur J Cardiothorac Surg 2006;30:628-636.
95. Inci I, Zhai W, Arni S, Inci D, Hillinger S, Lardinois D, Vogt P, Weder W. Fibrinolytic treatment improves the quality of lungs retrieved from non-heart-beating donors. J Heart Lung Transplant 2007;26:1054-1060.
96. Loehe F, Preissler G, Annecke T, Bittmann I, Jauch KW, Messmer K. Continuous infusion of nitroglycerin improves pulmonary graft function of non-heart-beating donor lungs. Transplantation 2004;77:1803-1808.
97. Rega FR, Wuyts WA, Vanaudenaerde BM, Jannis NC, Neyrinck AP, Verleden GM, Lerut TE, Van Raemdonck DE. Nebulized n-acetyl cysteine protects the pulmonary graft inside the non-heart-beating donor. J Heart Lung Transplant 2005;24:1369-1377.